Baker McKenzie advises Servier on the acquisition of a potential treatment for Fragile X syndrome

The pharmaceutical business Servier has received advice from Baker McKenzie about the purchase of KER-0193, a possible therapy for the biotechnology company Kaerus Bioscience’s Fragile X syndrome (FXS), the most prevalent hereditary cause of autism spectrum disorders (ASD).